Psoriasis triggered by infliximab in a patient with Behçet’s disease

Shergy WJ(2002)Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis J Rheumatol 29 667-677

Isern RA(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

Cooley DA(2002)Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab J Am Acad Dermatol 46 886-891

Harshbarger JL(2004)Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis J Rheumatol 31 1362-1368

Huffstutter JE(2004)Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease Ann Intern Med 140 404-406

Hughes GM(2010)Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet disease Br J Opthalmol 94 284-288

Hanauer SB(2011)Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy Br J Ophthalmol 95 1245-1250

Feagan BG(2008)Infliximab therapy for 2 patients with Vogt–Koyanagi–Harada syndrome Ocul Immunol Inflamm 16 167-171

Lichtenstein GR(2010)Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration Jpn J Ophthalmol 54 502-504

Mayer LF(2005)Psoriasis induced by anti-tumor necrosis factor therapy Arthr Rheum 52 2513-2518

Shergy WJ(2002)Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis J Rheumatol 29 667-677

Isern RA(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

Cooley DA(2002)Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab J Am Acad Dermatol 46 886-891

Harshbarger JL(2004)Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis J Rheumatol 31 1362-1368

Huffstutter JE(2004)Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease Ann Intern Med 140 404-406

Hughes GM(2010)Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet disease Br J Opthalmol 94 284-288

Hanauer SB(2011)Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy Br J Ophthalmol 95 1245-1250

Feagan BG(2008)Infliximab therapy for 2 patients with Vogt–Koyanagi–Harada syndrome Ocul Immunol Inflamm 16 167-171

Lichtenstein GR(2010)Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration Jpn J Ophthalmol 54 502-504

Mayer LF(2005)Psoriasis induced by anti-tumor necrosis factor therapy Arthr Rheum 52 2513-2518